AEON Biopharma, Inc. (AEON): Nasdaq/NYSE listing notice — AEON Biopharma gets second NYSE American delisting notice over $55M equity deficit

AEON Biopharma, Inc.

March 31, 2026 notice: not compliant with Section 1003(a)(ii) requiring ≥$4M stockholders' equity.
Stockholders' deficit ~$55M as of Dec 31, 2025; losses in 3 of last 4 fiscal years.
Prior non-compliance (Section 1003(a)(i)) from Feb 2025; NYSE American accepted compliance plan through Aug 3, 2026.
Stock continues trading under AEON with '.BC' indicator; company remains on noncompliant issuers list.
Failure to regain compliance by Aug 3, 2026 could lead to delisting; business operations unaffected.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(ii)).

Exchange: nyse american
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 1003(a)(ii)

Exact text from the filing

March 31, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) received an additional written notice of non-compliance (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires stockholders’ equity of $4.0 million or more if a listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reporte

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.